How has recombinant DNA technology changed the production of human growth hormone?
Recombinant DNA technology has fundamentally transformed the production of human growth hormone by enabling its synthesis in controlled, scalable laboratory environments rather than relying on limited biological sources.12
Before this advancement, the only available source of human growth hormone was extraction from human cadaver pituitaries. This was particularly problematic because, unlike insulin, the effects of growth hormone are species-specific, meaning animal-derived versions were not viable alternatives for human treatment.2
By utilizing recombinant DNA technology, scientists can insert the human gene responsible for growth hormone production into host cells, such as bacteria. These organisms act as biological "factories," synthesizing the protein in a controlled and consistent manner. This shift has significantly improved the safety, purity, and availability of the hormone, allowing for the large-scale production of life-saving therapies for growth disorders. Since its first approval in 1985, this technology has replaced older, invasive extraction methods with reliable, synthetic preparations.312